HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Platelet Membrane Glycoprotein IIb

Subscribe to New Research on Platelet Membrane Glycoprotein IIb

Platelet membrane glycoprotein IIb is an integrin alpha subunit that heterodimerizes with INTEGRIN BETA3 to form PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX. It is synthesized as a single polypeptide chain which is then postranslationally cleaved and processed into two disulfide-linked subunits of approximately 18 and 110 kDa in size.

Also Known As:

CD41 Antigen; CD41 Cell Surface Antigen; GP IIb; GPalpha IIb; HUPL-ml Surface Antigen; Integrin alpha IIb; Membrane Glycoprotein IIb; Plasma Membrane Glycoprotein IIb; Antigen, CD41; Antigen, HUPL-ml Surface; Glycoprotein IIb, Membrane; HUPL ml Surface Antigen; Surface Antigen, HUPL-ml; alphaIIb, Integrin; Antigens, CD41; CD41 Antigens; Integrin alphaIIb

Networked: 824 relevant articles (86 outcomes, 162 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Harrington, Robert A: 14 articles (05/2015 - 12/2002)
2.	Lincoff, A Michael: 14 articles (12/2008 - 02/2003)
3.	Ohman, E Magnus: 13 articles (12/2010 - 12/2002)
4.	De Luca, Giuseppe: 12 articles (07/2015 - 01/2008)
5.	Topol, Eric J: 12 articles (06/2006 - 12/2002)
6.	Roe, Matthew T: 11 articles (12/2010 - 09/2002)
7.	Moliterno, David J: 10 articles (05/2015 - 10/2002)
8.	Stone, Gregg W: 10 articles (03/2012 - 11/2003)
9.	Kereiakes, Dean J: 10 articles (01/2009 - 07/2002)
10.	White, Harvey D: 8 articles (05/2015 - 12/2002)

Related Diseases

1.	Myocardial Infarction 11/16/1999 - "During the period of pharmacological treatment, each trial demonstrated a significant reduction in the rate of death or nonfatal myocardial infarction in patients randomized to the GP IIb/IIIa inhibitor compared with placebo. " 02/01/2000 - "The pre-PCI administration of GP IIb/IIIa inhibitors is associated with a significant reduction in peri-procedural complications (-41% relative reduction of death or acute myocardial infarction in the 48 hours after PCI, p < 0.001). " 08/01/2000 - "The administration of GP IIb/IIIa antagonists has been shown to be effective in reducing myocardial infarction and cardial death when given before PTCA. " 04/01/2001 - "Furthermore, recent clinical trials with a small number of patients suggest that GP IIb/IIIa inhibitors in combination with low-dose fibrinolytics are safe and effective for the treatment of ST segment elevation myocardial infarction. " 07/01/2012 - "After first promising trials, GP IIb\IIIa inhibitors (GPI) have been widely used in cath labs for about a decade, significantly improving prognosis for patients with STSegment Elevation Myocardial Infarction (STEMI). "
2.	Acute Coronary Syndrome 02/01/2009 - "The emergency physicians support early identification of high-risk non-ST-elevation acute coronary syndrome patients and early administration of GP IIb-IIIa inhibitors, which are linked to improved patient outcomes. " 03/01/2000 - "These GP IIb/IIIa antagonists have been shown to be effective in improving outcomes among patients undergoing percutaneous coronary interventions and for the treatment of acute coronary syndromes. " 05/01/1997 - "[Inhibitors of platelet receptors GP IIB/IIIA: a new therapeutic class and its promise in the treatment of acute coronary syndromes]." 02/12/1999 - "The clinical efficacy of GP IIb/IIIa-antagonists for acute percutaneous coronary interventions and in the management of the acute coronary syndrome is established. " 01/01/2008 - "Based on clinical trials, GP IIb/IIIa receptor antagonists have been extensively studied and used in patients with acute coronary syndrome or during percutaneous coronary interventions. "
3.	Hemorrhage 10/01/2008 - "In our experience, percutaneous coronary intervention has high procedural success in dialysis patients and concomitant use of GP IIb/IIIa inhibitors is not associated with any major bleeding complications, making this a feasible, safe and effective revascularization option for patients on dialysis; however, this merits further study in a randomized prospective trial." 06/01/1999 - "Early clinical studies confirm improved early patency and more rapid electrocardiographic resolution, but increased bleeding complications, with the addition of GP IIb/IIIa antagonists to conventional fibrinolysis. " 10/01/1999 - "Strategies for improved management of bleeding complications in these patients, including the choice of a GP IIb-IIIa inhibitor, are clearly needed and are discussed in detail." 10/01/1999 - "This review summarizes current experience related to bleeding complications with various GP IIb-IIIa inhibitors and suggests strategies for improved management of bleeding in patients receiving these agents." 01/01/2014 - "Recent studies yield conflicting results and registry data have suggested that GP IIb/IIIa inhibitors may cause more bleeding than what trials indicate. "
4.	Unstable Angina 01/01/2005 - "Our study show that patients with unstable angina had a higher expression GP IIb/IIIa on the platelets membrane and elevated percentage of platelet microparticles confirm platelet activation. " 08/01/2000 - "BRING-UP 1 will be followed by BRING-UP 2, the aim of this latter being to assess the effects of beta-blocker therapy on populations underrepresented in randomized trials, and SET-UP, on the use of GP IIb/IIIa platelet receptor inhibitors in unstable angina. " 12/01/1998 - "Recent large-scale randomized trials have demonstrated the value of GP IIb/IIIa receptor inhibitors in reducing the risk of death and MI in unstable angina/non-Q-wave MI patients receiving pharmacologic management. " 12/01/1998 - "Recent large-scale randomized trials have demonstrated the value of GP IIb/IIIa receptor inhibitors in reducing the risk of death and MI in patients with unstable angina or those with MI with non-Q-wave abnormalities who are receiving pharmacologic management. " 01/01/2005 - "There was no significantly different in platelet GP IIb/IIIa expression after the antiplatelet therapy in patients with unstable angina."
5.	Thrombosis (Thrombus) 11/01/1999 - "New anti-platelet (GP IIb/IIIa) drugs seem to be very effective in the prevention and treatment of the thrombosis. " 09/01/2003 - "Platelet aggregation, a process mediated by GP IIb-IIIa, is responsible for the occlusive events in thrombosis: indeed, GP IIb-IIIa antagonists are effective in blocking arterial thrombosis. " 02/01/2000 - "This observation may contribute to a greater efficacy of GP-IIb/IIIa inhibitors for the treatment of thrombosis in atherosclerotic patients." 02/01/2002 - "The present study demonstrates that the inhibition of platelet GP Ib function by 6B4-Fab is a powerful intervention to prevent platelet thrombus formation in injured arteries without prolongation of the bleeding time; the latter is in contrast to the result after the inhibition of GP IIb/IIIa. " 01/01/2015 - "Early Gp IIb/IIIa inhibitor use may be considered as upstream therapy especially in high-risk patients, whereas the choice of periprocedural administration may be based on thrombus burden or in case of impaired haemodynamic conditions that may compromise oral drug absorption. "

Related Drugs and Biologics

1.	Glycoproteins (Glycoprotein)
2.	Heparin (Liquaemin)
3.	bivalirudin (Angiomax)
4.	abciximab (ReoPro)
5.	Aspirin (Acetylsalicylic Acid)
6.	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
7.	eptifibatide (Integrilin)
8.	clopidogrel (Plavix)
9.	tirofiban (Aggrastat)
10.	Enoxaparin (Lovenox)

Related Therapies and Procedures

1.	Angioplasty (Angioplasty, Transluminal)
2.	Stents
3.	Catheters
4.	Atherectomy
5.	Transplants (Transplant)